Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: Drug levels and clinical outcomes

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

New England Journal of Medicine · 2010 · 3.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

New England Journal of Medicine · 2012 · 2.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen et al. · New England Journal of Medicine · 2013 · 2.3K citations · Full text

Medicine, Pharmacokinetics, Pharmacotherapy +12

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Robert C. Gosselin, Dorothy Adcock, Shannon M. Bates et al. · Thrombosis and Haemostasis · 2018 · 386 citations · Full text

Medicine, Hematology, Pharmacology +17

Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects

Dagmar Kubitza, Michael Becka, Michael Zuehlsdorf et al. · The Journal of Clinical Pharmacology · 2007 · 330 citations

Medicine, Pharmacokinetics, Pharmacology +15